- Report
- April 2025
- 175 Pages
Global
From €3956EUR$4,490USD£3,409GBP
Increlex is a brand of recombinant human insulin-like growth factor-1 (rhIGF-1) used to treat growth failure in children with severe primary IGF-1 deficiency (Primary IGFD). It is also used to treat short stature associated with Turner syndrome in patients who have had an inadequate response to growth hormone therapy. Increlex is a recombinant form of IGF-1, a hormone that is naturally produced in the body and is essential for normal growth and development. It is administered as a subcutaneous injection and is available in two strengths: 0.04 mg/kg and 0.08 mg/kg.
Increlex is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, metabolism, and other bodily functions.
Companies in the Increlex market include Pfizer, Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more